Patents by Inventor Somasekar Seshagiri

Somasekar Seshagiri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240228631
    Abstract: Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.
    Type: Application
    Filed: November 3, 2023
    Publication date: July 11, 2024
    Inventors: Stephane ANGERS, Sachdev SIDHU, Levi BLAZER, Jarrett ADAMS, Somasekar SESHAGIRI
  • Publication number: 20240132600
    Abstract: Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.
    Type: Application
    Filed: November 2, 2023
    Publication date: April 25, 2024
    Inventors: Stephane ANGERS, Sachdev SIDHU, Levi BLAZER, Jarrett ADAMS, Somasekar SESHAGIRI
  • Publication number: 20230203466
    Abstract: Human ACE2 variants are provided including methods of use thereof. The ACE2 receptor variants may be used for diagnosis and treatment of COVID-19.
    Type: Application
    Filed: April 5, 2021
    Publication date: June 29, 2023
    Inventors: Somasekar Seshagiri, Eric Stawiski, Kushai Suryamohan, Ravi Gupta, Jagath Reddy Junutula
  • Publication number: 20230118983
    Abstract: Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.
    Type: Application
    Filed: June 22, 2022
    Publication date: April 20, 2023
    Inventors: Stephane ANGERS, Sachdev SIDHU, Levi BLAZER, Jarrett ADAMS, Somasekar SESHAGIRI
  • Publication number: 20210025008
    Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: June 8, 2020
    Publication date: January 28, 2021
    Inventors: Frederic J. de Sauvage, Eric William Stawiski, Steffen Durinck, Zora Modrusan, Somasekar Seshagiri
  • Publication number: 20200172631
    Abstract: The present disclosure relates to somatic ErbB2 mutations in cancer and provides methods of identifying, diagnosing, and prognosing ErbB2-positive cancers. The present disclosure further provides methods of treating cancer, including certain subpopulations of patients. The mutations are in the transmembrane domain or juxtamembrane domain of ErbB2.
    Type: Application
    Filed: October 24, 2019
    Publication date: June 4, 2020
    Applicant: GENENTECH, INC.
    Inventor: Somasekar Seshagiri
  • Publication number: 20200138944
    Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: October 9, 2019
    Publication date: May 7, 2020
    Applicant: Genentech, Inc.
    Inventors: Steffen Durinck, Bijay Jaiswal, Zora Modrusan, Somasekar Seshagiri, Eric Stawiski, Na Zhang
  • Publication number: 20180360835
    Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.
    Type: Application
    Filed: September 5, 2018
    Publication date: December 20, 2018
    Applicant: Genentech, Inc.
    Inventors: Kui Lin, Elizabeth Punnoose, Somasekar Seshagiri
  • Publication number: 20180250394
    Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: December 8, 2016
    Publication date: September 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Steffen Durinck, Bijay Jaiswal, Zora Modrusan, Somasekar Seshagiri, Eric Stawiski, Na Zhang
  • Publication number: 20180235968
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Application
    Filed: April 16, 2018
    Publication date: August 23, 2018
    Applicant: GENENTECH, INC.
    Inventor: Somasekar SESHAGIRI
  • Patent number: 9631240
    Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: April 25, 2017
    Assignee: Genentech, Inc.
    Inventors: Zhengyan Kan, Denise M. Kenski, Brock Peters, Somasekar Seshagiri
  • Publication number: 20170065588
    Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.
    Type: Application
    Filed: August 15, 2016
    Publication date: March 9, 2017
    Inventors: Kui Lin, Elizabeth Punnoose, Somasekar Seshagiri
  • Publication number: 20150290196
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Application
    Filed: February 18, 2015
    Publication date: October 15, 2015
    Applicant: GENENTECH, INC.
    Inventor: Somasekar Seshagiri
  • Patent number: 8987266
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: March 24, 2015
    Assignee: Genentech, Inc.
    Inventor: Somasekar Seshagiri
  • Publication number: 20150010537
    Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.
    Type: Application
    Filed: March 6, 2014
    Publication date: January 8, 2015
    Applicant: Genentech, Inc.
    Inventors: Zhengyan Kan, Denise M. Kenski, Brock Peters, Somasekar Seshagiri
  • Publication number: 20140298493
    Abstract: The invention concerns the development of a PIK3CA H1047R knock-in non-human animal breast cancer model, and its use for identification of a spontaneous loss-of-function TP53 mutation involved in spindle cell tumor formation. The invention further concerns the identification of additional somatic mutations and copy number aberrations in the breast tumors using this model, and methods and means for the diagnosis and treatment of breast cancer.
    Type: Application
    Filed: July 26, 2012
    Publication date: October 2, 2014
    Inventor: Somasekar Seshagiri
  • Patent number: 8680041
    Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: March 25, 2014
    Assignee: Genentech, Inc.
    Inventors: Zhengyan Kan, Denise M. Kenski, Brock Peters, Somasekar Seshagiri
  • Publication number: 20140031259
    Abstract: Methods for predicting sensitivity to cancer treatments by assessing biomarkers and combinations of biomarkers include evaluating the presence of mutations to Akt, wherein the presence of said mutations correlates with the sensitivity of Akt inhibitors.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 30, 2014
    Applicant: GENENTECH, INC.
    Inventors: Kui Lin, Elizabeth Punnoose, Somasekar Seshagiri
  • Publication number: 20140011821
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Application
    Filed: August 21, 2013
    Publication date: January 9, 2014
    Applicant: GENENTECH, INC.
    Inventor: Somasekar Seshagiri
  • Publication number: 20130324419
    Abstract: Methods of capturing and sequencing target nucleic acid molecules are provided. Methods of determining the methylation status of genomic DNA are also provided.
    Type: Application
    Filed: August 25, 2011
    Publication date: December 5, 2013
    Inventor: Somasekar Seshagiri